Efficacy of crizotinib in ALK mutant non-small cell lung cancers that are positive by IHC but negative by FISH compared to FISH positive cases (Record no. 83266)

000 -LEADER
fixed length control field 02637nab a22003137a 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 180813b2018 xxu||||| |||| 00| 0 eng d
100 ## - MAIN ENTRY--PERSONAL NAME
Personal name Zanwar S
245 ## - TITLE STATEMENT
Title Efficacy of crizotinib in ALK mutant non-small cell lung cancers that are positive by IHC but negative by FISH compared to FISH positive cases
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT)
Date of publication, distribution, etc 2018
300 ## - PHYSICAL DESCRIPTION
Extent
500 ## - GENERAL NOTE
General note Address for correspondence: kprabhash1@gmail.com
520 ## - SUMMARY, ETC.
Summary, etc BACKGROUND: A small proportion of Non-Small Cell Lung Cancers (NSCLC) are detected with Anaplastic Lymphoma Kinase (ALK) mutation by immunohistochemistry (IHC) but are negative by Fluorescence in situ Hybridization (FISH). Data on responses and outcome of this subset of patients when treated with crizotinib is limited. We analyzed the outcomes of such patients who received crizotinib. PATIENTS AND METHODS: Demographics, treatment details, response to treatment, date of progression and date of death were collected for patients who were IHC positive and FISH negative for ALK mutation from a prospectively maintained database. Depending upon feasibility, patients received either platinum based doublet chemotherapy or the ALK inhibitor crizotinib as first line therapy. Outcomes were compared to our previously published historical cohort of FISH positive patients who were treated with crizotinib. RESULTS: Thirteen patients were detected to be IHC+/FISH- and out of these seven received crizotinib. Objective response rate for crizotinib was 57.15% with an estimated mean PFS of 9.6 months (95% CI 3.8 -15.5 months). The difference in ORR of ALK IHC+/FISH- when compared to our historical cohort of ALK FISH positive treated with crizotinib was not statistically significant (57.15% vs 69.8%; P = 0.265). Estimated mean and median PFS was similar between the two cohorts (median PFS 6.0 months vs 14 months; mean PFS 9.6 months versus 14.7 months; P = 0.467). CONCLUSION: NSCLCs positive for ALK mutation by IHC but not detected by FISH show good response to crizotinib and merit treatment with the same.
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Anaplastic lymphoma kinase positive
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Crizotinib
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Fluorescence in situ hybridization
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Immunohistochemistry
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Noronha V
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Joshi A
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Patil VM
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Kaushal R
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Chougule A
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Janu A
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Mahajan A
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Kapoor A
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Prabhash K
Relator term Corresponding author
773 ## - HOST ITEM ENTRY
Main entry heading Indian Journal of Cancer
Place, publisher, and date of publication Mumbai : Medknow Publications, 2017
Relationship information Vol. 54, no. 4, p. 678-680
International Standard Serial Number 0019-509X
906 ## - LOCAL DATA ELEMENT F, LDF (RLIN)
Dept Medical Oncology
Corporate name TMC
Article Type Original Article
Country type National
Added Entry TMH
PMID 30082557
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Item type Articles
Holdings
Withdrawn status Lost status Source of classification or shelving scheme Damaged status Not for loan Permanent location Current location Date acquired Barcode Date last seen Koha item type
          Tata Memorial Hospital Tata Memorial Hospital 2018-08-13 AR19118 2018-08-13 Articles

Powered by Koha